Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010333 | 0.85 | EGFR (0.55) | EGFRTDO2CYP2A6 | |
| SCHEMBL27741827 | 0.81 | EGFR (0.55) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL4156184 | 0.81 | EGFR (0.55) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL28016944 | 0.76 | EGFR (0.49) | EGFRPIK3CDPIK3CAAR | |
| Quinazoline SCHEMBL28634018 | 0.75 | EGFR (0.69) | EGFRPIK3CDPIK3CACYP2A6ALDH1A1 | |
| SCHEMBL29376141 | 0.75 | PIK3CG (0.38) | EGFRCYP2A6ALDH1A1 | |
| SCHEMBL31435667 | 0.75 | EGFR (0.51) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL276644 | 0.75 | EGFR (0.60) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL29935890 | 0.74 | CYP2A6 (0.42) | EGFRCYP2A6ALDH1A1 | |
| SCHEMBL2012642 | 0.74 | CYP2A6 (0.42) | EGFRCYP2A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-109608454-A | A kind of new method synthesizing 6 hydrogen-pyridine [1,2-c] quinazoline -6- ketone compounds | 河南师范大学 | 2019-04-12 | — | — | CN | claimed |
| CN-101495914-B | Liquid crystal display operating in a vertically aligned mode | CRYSOPTIX LTD | 2011-08-10 | — | — | CN | claimed |
| CN-101495914-A | Liquid crystal display operating in a vertically aligned mode | CRYSOPTIX LTD (JP) | 2009-07-29 | — | — | CN | claimed |
| CN-101490588-A | Backlight module and liquid crystal display comprising same | CRYSOPTIX KK (JP) | 2009-07-22 | — | — | CN | claimed |
| CN-101384598-A | Organic compound, anisotropic optical film and method for producing the same | CRYSOPTIX LTD (JP) | 2009-03-11 | — | — | CN | claimed |
| CN-101375188-A | Multilayer polarizer | CRYSOPTIX KK (JP) | 2009-02-25 | — | — | CN | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20250340538-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4422747-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2024-09-04 | — | — | EP | disclosed |
| US-20050020833-A1 | Process for synthesizing antifolates | BIONUMERIK PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1343761-A1 | PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | Schering Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6472394-B1 | MCH antagonists and their use in the treatment of obesity | SCHERING CORPORATION | 2002-10-29 | — | — | US | disclosed |
| WO-2002051809-A1 | PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
| CN-1065744-C | Treatment of diseases associated with platelet derived growth factor such as cancer | SUGEN INC (US) | 2001-05-16 | — | — | CN | disclosed |
| CN-1128496-A | Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor | SUGEN INC (US) | 1996-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | EGFR 1008/4885PIK3CD 1737/4885PIK3CA 1797/4885 |
| US-20050020833-A1 | Process for synthesizing antifolates | DHFR, FDPS, FOLR1 | EGFR 1769/4885PIK3CD 3096/4885PIK3CA 1844/4885 |
| US-20250340538-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | EGFR 2596/4885PIK3CD 2187/4885PIK3CA 1475/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | EGFR 1500/4885PIK3CD 855/4885PIK3CA 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.